微生态制剂对老年肠道菌群失调相关性腹泻的影响分析  

Therapeutic effect of microecological preparation plus Rifaximin on diarrhea associated with intestinal flora imbalance in elderly patients

作　　者：章科清 江琴 张海兵 Ke-Qing Zhang;Qin Jiang;Hai-Bing Zhang(Clinical Laboratory,Hangzhou Geriatric Hospital,Hangzhou 310000,Zhejiang Province,China;Department of Gastroenterology,Hangzhou First People＇s Hospital,Hangzhou 310000,Zhejiang Province,China)

机构地区：[1]杭州市老年病医院检验科,浙江省杭州市310000 [2]杭州市第一人民医院消化内科,浙江省杭州市310000

出　　处：《世界华人消化杂志》2018年第33期1933-1938,共6页World Chinese Journal of Digestology

摘　　要：目的分析研究微生态制剂培菲康联合利福昔明对老年人肠道菌群失调相关性腹泻患者炎性因子及肠道屏障功能的影响.方法医院选择2015/08-2017/12收治的333例老年人肠道菌群失调相关性腹泻患者作为研究对象.按照随机数表法将患者分至观察组(167例)及对照组(166例).观察组采用微生态制剂培菲康联合利福昔明治疗,对照组采用微生态制剂培菲康治疗.分析研究微生态制剂培菲康联合利福昔明对老年人肠道菌群失调相关性腹泻患者炎性因子及肠道屏障功能的影响.结果治疗前,两组患者TNF-α、IL-10水平、临床症状评分无统计学差异(P>0.05).治疗后,两组患者的炎症因子及临床症状评分均得到明显降低,且观察组炎性因子[TNF-α:254.18 ng/L±38.71 ng/L、IL-10:74.36ng/L±19.22ng/L]和临床症状评分(2.22±0.71)更低于对照组,差异具有统计学意义(P<0.05).治疗后,观察组出现肠道细菌减少(5)、杆球比例倒置(4)、真菌感染(3)例数均少于对照组,差异具有统计学意义(P<0.05).观察组的治疗总体有效率为94.01%,对照组仅为68.67%,差异具有统计学意义(P<0.05).治疗过程中,两组均出现恶心呕吐、头痛头晕、肝功能损伤,观察组发生率为2.36%,对照组为1.98%,差异不具有统计学意义(P>0.05),且通过对症治疗均能够得到改善.结论微生态制剂培菲康联合利福昔明治疗老年人肠道菌群失调相关性腹泻患者可以更好的改善降低炎症因子水平,改善肠道屏障功能,减轻临床症状,有助于提高治疗效果,值得推广应用.AIMTo evaluate the effect of microecological preparation （Bifecan） plus Rifaximin on inflammatory factors and intestinal barrier function in elderly patients with diarrhea associated with intestinal fora imbalance.METHODSFrom August 2015 to December 2017, 333 elderly patients with diarrhea associated with intestinal fora imbalance were selected as subjects. The patients were randomly divided into an observation group （167 cases） and a control group （166 cases）. The observation group was treated with Bifecan plus Rifaximin, while the control group was treated with Bifecan alone. The effect of Bifecan plus Rifaximin on inflammatory factors and intestinal barrier function was then analyzed.RESULTSThere was no significant difference in NIHSS score, mRS score, plasma viscosity, or erythrocyte aggregation index between the two groups before treatment （P 〉 0.05）. After treatment, the infammatory factors and clinical symptom scores were signifcantly reduced in both groups, and the inflammatory factors （TNF-α： 254.18 ng/L ± 38.71 ng/L, IL-10： 74.36 ng/L ± 19.22 ng/L） and clinical symptom score （2.22 ± 0.71） were signifcantly lower in the observation group than in the control group （P 〈 0.05）. After treatment, the numbers ofcases with decreased intestinal bacteria （5）, inverse ratio between bacilli and cocci （4）, and fungal infection （3） were signifcantly lower in the observation group than in the control group （P 〈 0.05）. The overall effective rate was signifcantly higher in the observation group than in the control group （94.03% vs 87.69%, P 〈 0.05）.CONCLUSIONBifecan combined with Rifaximin can improve the levels of inflammatory factors and intestinal barrier function and alleviate clinical symptoms in elderly patients with diarrhea associated with intestinal fora imbalance.

关 键 词：微生态制剂 培菲康 利福昔明 老年 肠道菌群失调相关性腹泻 炎性因子 肠道屏障功能 

分 类 号：R574.62[医药卫生—消化系统]